Rice Hall James & Associates LLC Takes $23.32 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC has acquired a new stake worth $23.32 million in BioCryst Pharmaceuticals, Inc., making it the firm's 25th largest holding. Other institutional investors like RA Capital and Deerfield Management also increased their positions, contributing to 85.88% institutional ownership. BioCryst Pharmaceuticals recently exceeded analyst estimates with quarterly revenue of $218.25 million and EPS of $0.30, maintaining a "Moderate Buy" consensus rating among analysts.
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares
BioCryst Pharmaceuticals reported a significant swing to profit in Q2 2026 with US$218.25 million in revenue and US$78.4 million net income, alongside raising its full-year revenue outlook to US$690-US$715 million. Despite a strong quarter driven by ORLADEYO, the company still faces a substantial year-to-date net loss, highlighting its continued reliance on this single drug and potential vulnerability to market pressures. Investors should consider the upgraded guidance against the company's concentration in ORLADEYO and broader financial performance.
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares
BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss of US$643.42 million, highlighting its reliance on its key drug ORLADEYO. Investors will need to weigh the upgraded revenue guidance and the potential of ORLADEYO against the company's concentrated revenue stream and overall year-to-date performance.
Discipline and Rules-Based Execution in BCRX Response
This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The analysis emphasizes disciplined, rules-based execution with specific entry zones, targets, and stop losses.
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares
RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The filing indicates shared voting and dispositive power over these shares, with Peter Kolchinsky and Rajeev Shah also deemed beneficial owners for reporting purposes.
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX
Wedge Capital Management L.L.P. NC recently purchased 380,801 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for approximately $3.8 million, now holding 0.15% of the company. Institutional investors collectively own 85.88% of the biotechnology firm. BioCryst Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $0.30 EPS and a 33.6% year-over-year revenue increase, though analysts still anticipate a full-year loss.
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. increased its stake in BioCryst Pharmaceuticals Inc. by 51.6% in the second quarter, purchasing an additional 120,097 shares. This brings their total holdings to 353,044 shares, valued at $3.53 million. Other institutional investors have also adjusted their positions in the biotechnology company, which recently reported stronger-than-expected earnings and has received a "Moderate Buy" consensus rating from analysts.
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Bank of America Corp DE significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX), purchasing over 3.5 million additional shares to own 2% of the company, valued at $48.5 million. This move comes as BioCryst reported strong quarterly revenues, beating analyst estimates, and analysts maintain a "Moderate Buy" rating for the stock. Despite reporting negative net margins, institutional investors hold a substantial portion of BioCryst shares.
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
BioCryst Pharmaceuticals reported strong Q2 2026 results, with total revenue up 45% year-over-year to $218.3 million and ORLADEYO net revenue increasing 10% to $158.2 million. The company is transitioning to an external innovation model, closing its Birmingham research facility, and has launched its pediatric ORLADEYO oral pellets, which are exceeding initial expectations. BioCryst raised its total revenue guidance for 2026 to $690 million-$715 million, driven by licensing revenue, and maintained ORLADEYO revenue guidance while demonstrating strong operating profitability and cash flow.
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside
BioCryst Pharmaceuticals, Inc. (BCRX) presents a significant growth opportunity in the biopharmaceutical sector, driven by its focus on rare diseases and a strong pipeline including ORLADEYO. Analysts project a substantial 111.57% potential upside with an average target price of $20.82, fueled by robust revenue growth despite current unprofitability. The company's strategic partnerships and innovative R&D position it well for long-term gains, making it an attractive prospect for growth-oriented investors.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock price increase by 6% in mid-day trading following strong quarterly results, where the company exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $20.60, despite varied individual ratings. Institutional investors have also adjusted their stakes in the biotechnology company.
BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance
BioCryst Pharmaceuticals (BCRX) is potentially 54% undervalued, with a fair value estimated at $21.30 per share against a last close of $9.84. This outlook follows a strong Q2 2026 report showing higher revenue, improved net income, and a raised full-year revenue forecast, coupled with recent positive stock performance. However, this valuation depends on strong, sustainable revenue growth for ORLADEYO and the successful progress of early-stage programs, while also acknowledging inherent risks.
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
BioCryst Pharmaceuticals achieved profitability in 2025 and saw a significant revenue increase in Q2 2026, leading to speculation about its acquisition. Takeda is considered the top potential buyer due to BioCryst's drug navenibart directly threatening Takeda's HAE franchise, with AstraZeneca ranking second. Other potential acquirers include Amgen, Sanofi, and Novartis, though each has limiting factors.
BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had approximately 411 employees worldwide as of March 2026, representing a 3.8% decline since 2023. The company is actively hiring, though job postings have decreased significantly, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, and the average salary is $162,651.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen
BioCryst Pharmaceuticals (NASDAQ:BCRX) has been upgraded to a "strong-buy" rating by Wall Street Zen. The company reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue increasing 33.6% year over year. Despite a recent price target decrease from Royal Bank Of Canada, other analysts maintain generally positive outlooks, with an average "Moderate Buy" rating and a consensus price target of $20.60.
State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing
State Street Corporation has disclosed a beneficial ownership of 15,191,098 shares of BioCryst Pharmaceuticals, Inc. common stock, which represents a 6% stake in the company. This disclosure was made via a Schedule 13G filing, indicating a passive investment. While State Street has shared dispositive power over all these shares, its shared voting power extends to 14,586,276 shares, primarily through its investment management subsidiaries.
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors
BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of US$218.25 million and a net income of US$78.40 million, while raising its full-year 2026 revenue guidance to US$690 million to US$715 million. This positive short-term outlook, driven by ORLADEYO sales, contrasts with a six-month net loss of US$643.42 million. Investors are balancing the strong performance of ORLADEYO and increased revenue guidance against concerns about product concentration and the company's overall financial health.
BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure
BioCryst Pharmaceuticals will lay off 47 employees starting October 7, 2026, as it closes its Birmingham-area Discovery Center of Excellence. This decision is part of a strategic shift to focus on externally sourced innovation and reduce operating costs, with the company lowering its 2026 non-GAAP operating expense guidance. The layoffs stem from a broader move to discontinue internal drug discovery operations and leverage external capabilities for future rare disease therapies.
BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside
BioCryst Pharmaceuticals, Inc.'s average 12-month price target has been lowered slightly from $21 to $20.82 by 11 analysts, with forecasts ranging from $12 to $32 per share. This new target suggests a potential upside of approximately 131% based on the Aug. 4 closing price. The consensus rating for the stock remains a "Buy" from all covering analysts.
Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
Dimensional Fund Advisors LP significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 119% in the first quarter, now holding 2.69 million shares valued at $25.6 million. This move is consistent with a generally positive outlook from analysts, who have assigned a "Moderate Buy" rating with an average price target of $20.80. BioCryst also reported strong quarterly earnings, surpassing analyst expectations with $218.25 million in revenue and $0.30 EPS.
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating
RBC Capital has adjusted its price target for BioCryst Pharmaceuticals (BCRX) to $13, down from $14, while maintaining an Outperform rating on the stock. This revision comes amidst recent company news, including the discontinuation of internal drug discovery programs and a positive earnings report for Q2 2026. The company reported increased earnings and revenue, leading to an updated full-year 2026 revenue outlook.
BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength
BioCryst Pharmaceuticals (BCRX) reported a significant profit surge in Q2 2026, driven by strong ORLADEYO revenue and a European licensing deal, yet its stock remained largely unchanged. While ORLADEYO shows real patient uptake and the company has solid liquidity, concerns remain about its reliance on a single product and the long wait for pipeline readouts. The article discusses both bullish and bearish arguments surrounding the company's financial performance and future prospects.
BioCryst Reports Second Quarter 2026 Financial Results
BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, driven by the successful launch of ORLADEYO oral pellets for pediatric patients and advancement in its pipeline. BioCryst also announced a strategic shift towards external innovation and cost discipline, aiming for continued growth and profitability.
BioCryst Reports Second Quarter 2026 Financial Results
BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue reaching $218.3 million and ORLADEYO net revenue at $158.2 million, leading to an operating profit of $98.5 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, while also announcing the commencement of shipping ORLADEYO oral pellets for pediatric patients and completing enrollment in its pivotal navenibart study. These achievements underscore BioCryst's focus on expanding ORLADEYO's market, advancing its pipeline, and optimizing its cost structure through strategic shifts towards external innovation.
Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook
BioCryst Pharmaceuticals reported Q2 2026 earnings that surpassed Wall Street expectations, with adjusted earnings of $0.30 per share against an estimated $0.16, and revenue of $218.3 million compared to a forecast of $185.69 million. The company raised its full-year 2026 revenue guidance to $690 million-$715 million and lowered its non-GAAP operating cost guidance due to strong performance of its main drug ORLADEYO and a licensing payment. Shares rose over 5% in premarket trading following the positive results and outlook.
BioCryst Pharmaceuticals Q2 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported strong Q2 results, with ORLADEYO revenue increasing 10% year-over-year and pediatric oral-pellet shipments commencing. The company maintained its 2026 ORLADEYO revenue outlook and reduced its non-GAAP operating cost guidance by ending internal drug discovery. BioCryst also completed enrollment for its pivotal ALPHA-ORBIT trial for navenibart and ended the quarter with over $350 million in cash, shifting focus to external innovation and profitable growth.
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M
BioCryst Pharmaceuticals, Inc. (BCRX) reported Q2 revenue of $218.2 million, significantly exceeding FactSet's estimate of $183.3 million. The company also updated its earnings guidance for the full year 2026 and announced increased Q2 earnings and revenue. Additionally, Wedbush adjusted BioCryst Pharmaceuticals' price target to $20 from $21, while maintaining an Outperform rating.
BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients
BioCryst Pharmaceuticals reported strong Q2 2026 financial results, with total revenue up 34% year-over-year to $218.3 million and ORLADEYO revenue reaching $158.2 million. The company has begun shipping ORLADEYO oral pellets to pediatric HAE patients and raised its full-year total revenue guidance while lowering operating expense guidance. BioCryst is also advancing its pipeline and focusing on external innovation after discontinuing internal discovery programs.
BioCryst Reports Second Quarter 2026 Financial Results
BioCryst Pharmaceuticals reported strong second quarter 2026 financial results with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million, resulting in an operating profit of $98.5 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, while also announcing the initiation of shipments for ORLADEYO oral pellets for pediatric patients and completing enrollment in its pivotal navenibart study. These results reflect BioCryst's focus on expanding ORLADEYO's reach and advancing its pipeline through strategic external innovation and cost discipline.
North Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham area
BioCryst Pharmaceuticals, a biotechnology company based in Durham, North Carolina, is closing its Birmingham area facilities in Hoover and laying off 47 workers. This strategic move involves discontinuing internal discovery programs and shutting down its Discovery Center of Excellence, ending the company's decades-long research presence in the Birmingham metropolitan area. BioCryst's CEO, Charlie Gayer, stated that the decision aims to leverage the company’s financial position and build a sustainable rare disease pipeline.
BioCryst earnings on deck: Can Orladeyo sustain momentum?
BioCryst Pharmaceuticals is set to release its second-quarter earnings, with investors focused on the revenue performance of its flagship hereditary angioedema therapy, Orladeyo. Analysts anticipate strong sequential revenue growth, and the company is undergoing a strategic transformation involving cost reductions and the integration of a new acquisition, navenibart. The earnings report will be crucial for understanding if BioCryst can maintain Orladeyo's growth and successfully implement its leaner business model.
Behavioral Patterns of BCRX and Institutional Flows
The article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), highlighting a weak near and mid-term sentiment but a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance levels.
BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?
BioCryst Pharmaceuticals (BCRX) stock has seen a recent decline after a strong year, leading to questions about its valuation. Despite being 58.6% undervalued according to a popular narrative with a fair value of $21.30 against its current $8.81, the company faces pressure points like reliance on ORLADEYO and early-stage pipeline bets. Investors are encouraged to review the company's risks and rewards to form their own conclusions.
ETFs Investing in BioCryst Pharmaceuticals, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of BioCryst Pharmaceuticals, Inc. (BCRX). The ETFs are sorted by their market value and provide details such as issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return. The information aims to help investors find accessible and diversified opportunities for investing in BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:BCRX
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) generated $874.84 million in revenue last year, primarily from its Oral Small-molecule and Injectable Protein Therapeutics segment. This represents a significant increase from $450.71 million in the previous year. The United States was the largest contributor to revenue, accounting for $548.78 million.
BioCryst Pharmaceuticals Inc (BCRX) Institutional Confidence
BioCryst Pharmaceuticals Inc (BCRX) has a high institutional shareholding score of 10.00, ranking 1st in its industry, despite a recent 10.51% quarter-over-quarter decrease in institutional shareholding proportion. The largest institutional shareholder is James Simons, and notable institutional holders include BlackRock, RA Capital Management, and Deerfield Management, with Janus Henderson Investors showing a significant increase in holdings.
BCRX|BioCryst Pharmaceuticals Inc|Price:9.609|Chg%:-0.131
This article provides a comprehensive stock analysis of BioCryst Pharmaceuticals Inc (BCRX), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership, a consensus "Buy" rating from analysts with a high target price, and stable short-term price expectations despite recent market weakness. The company's focus on rare diseases and successful products like ORLADEYO contribute to its positive outlook.
BioCryst Pharmaceuticals Inc (BCRX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of BioCryst Pharmaceuticals Inc (BCRX), noting its current valuation score of 8.70, ranking 95th in its industry. It highlights the company's P/E ratio of -5.56 and states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Rice Hall James & Associates LLC Acquires 325,959 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC significantly increased its stake in BioCryst Pharmaceuticals by 17.1% in the first quarter, adding 325,959 shares to own a total of 2,230,105 shares valued at approximately $21.2 million. Institutional ownership of BioCryst remains high at 85.88%, with numerous other hedge funds also adjusting their positions. Despite the company missing its latest earnings estimates, analysts maintain a "Moderate Buy" rating with a consensus price target of $20.80.
BioCryst Pharmaceuticals Inc (BCRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of BioCryst Pharmaceuticals Inc (BCRX), listing its major shareholders and institutional holdings. It provides a breakdown of investor types, institutional shareholding over several quarters, and recent shareholder activities. The data highlights significant investors like BlackRock, RA Capital Management, and Deerfield Management.
BioCryst Pharmaceuticals, Inc. Revenue Breakdown – MUN:BO1
BioCryst Pharmaceuticals, Inc. (MUN:BO1) reported a total revenue of €744.85 million last year, primarily driven by its Oral Small-molecule and Injectable Protein Therapeutics segment. The United States was the largest geographical contributor, accounting for €467.24 million of the revenue. This represents a significant increase from the previous year's total revenue of €435.38 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares passed above their 200-day moving average on Thursday, trading as high as $9.48. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $20.80, despite the company reporting a wider-than-expected quarterly loss. Institutional investors have also recently adjusted their positions in the company, with 85.88% of the stock owned by institutional investors and hedge funds.
Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data
This article provides fundamental and financial data for Biocryst Pharmaceuticals Inc. (BCRX), including its current stock price, market capitalization, dividend yield, and analyst ratings. It also highlights recent news like the appointment of a new Chief Scientific Officer and mentions that Wall Street analysts project a significant surge for the stock.
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas
This article provides the latest stock price, analysis, news, and trading ideas for BioCryst Pharmaceuticals Inc. (BCRX). It includes current market data such as stock price, market cap, volume, 52-week high/low, PE ratio, and recent news headlines related to the company and the biotech sector. The article also highlights top discussions from the platform.
BCRX Q2'26 Earnings: revenue estimate is 183.28M USD
BioCryst Pharmaceuticals, Inc. (BCRX) is scheduled to announce its Q2'26 earnings on July 30. Analysts estimate revenue to be $183.28 million and earnings per share (EPS) at $0.15 for the quarter. The article provides a table of past reported and estimated revenue and EPS figures, along with surprise percentages.
(BCRX) Movement Within Algorithmic Entry Frameworks
The article details an algorithmic analysis of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), identifying divergent sentiment across various time horizons and an exceptional 48.0:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis. The analysis suggests choppy conditions for BCRX based on the observed sentiment.
How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals
BioCryst Pharmaceuticals recently appointed David W. Jenkins as its first Chief Scientific Officer to lead efforts in external innovation and partnerships for rare disease therapies. This move signals BioCryst's commitment to expanding its pipeline beyond its primary drug, ORLADEYO, though near-term focus remains on ORLADEYO's performance. The company's future revenue and earnings projections, heavily reliant on pipeline diversification, suggest a potential upside for investors.
BioCryst to Report Second Quarter 2026 Financial Results on August 5
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. The company is focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BioCryst to Report Second Quarter 2026 Financial Results on August 5
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Information for the webcast and replay will be available on BioCryst's investor relations website.
BioCryst schedules a look at second-quarter results for Aug. 5
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. The company's prior earnings-date announcements have typically preceded slight negative 24-hour stock price reactions.
